Final results of the rights offering

Reference is made to the notice to the stock exchange dated 10 June 2010. The
allocation from the rights offering, which closed on 9 June 2010 at 17:30 has
been resolved by the Board of PCI Biotech Holding ASA on 15 June 2010.

A total of 2,250,000 offered shares at NOK 40.00 per share have been allocated.
It was subscribed for a total of 3,367,449 shares.

Approximately 65 per cent (approximately 2.2 million shares) of the offered
shares were subscribed for by utilising subscription rights. Approximately 35
per cent (approximately 0.9 million shares) of the total subscribed shares were
oversubscribed or subscribed for without subscription rights.

Based on the allocation principles described in the prospectus dated 25 May
2010, 2.18 million new shares were allocated to subscribers according to held
subscription rights, and 0.06 million new shares were allocated to holders of
subscription rights that oversubscribed. No allocation was made to subscribers
without subscription rights.

Through the rights offering PCI Biotech Holding ASA will receive gross proceeds
amounting to NOK 90 million.

Notice of allocation and payment instructions will be sent out on 15 June 2010.
Payment date will be 17 June 2010 and all investors being allotted offered
shares must ensure that sufficient funds are available on the bank account
stated in the subscription form within 17 June 2010. The new shares will be
registered immediately after the rights offering has been fully paid and
registered with the Norwegian Register of Business enterprises. Such
registration is expected on or about 21 June 2010.

As per completion of the rights offering, PCI Biotech Holding ASA will issue
2,250,000 new shares with a nominal value of NOK 3.00, increasing its share
capital by NOK 6,750,000 to NOK 22,999,170, corresponding to a total of
7,666,390 shares in the company with a nominal value of NOK 3.00 per share.

The new shares may not be transferred or traded before they are fully paid and
the share capital increase has been registered with the Norwegian Register of
Business Enterprises and the new shares registered in the VPS.

The rights offering is managed by DnB NOR Markets and Fondsfinans ASA.

Contact information:

PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker

Per Walday, CEO (pw@pcibiotech.no), Mobile: +47 917 93 429

Bernt-Olav Røttingsnes, CFO (bor@pcibiotech.no), Mobile: +47 913 47 021


This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)


[HUG#1424088]